Abstracts tagged "physical function and rheumatoid arthritis (RA)"

Abstract Number: 420 • 2014 ACR/ARHP Annual Meeting
Less Is More: The Shorter Physical Function Measure Promis-PF10a Outperforms HAQ in an Ethnically Diverse, Urban Rheumatoid Arthritis Clinic Population
Elizabeth R. Wahl¹, Andrew J. Gross², R Krishna Chaganti¹, Lianne S. Gensler³, Vladimir Chernitskiy¹, Laura Trupin², Patricia P. Katz² and Jinoos Yazdany², ¹Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Patient-reported outcome measures are important tools that assess the impact of disease on patients' lives; in RA, patient-reported physical function is especially relevant. In…
Abstract Number: 1934 • 2013 ACR/ARHP Annual Meeting
Scores On The Multidimensional Health Assessment Questionnaire (MDHAQ) For “Walk 2 Miles Or 3 Kilometers,” “Poor Sleep,” and “Participate In Recreation,” Are Higher, Indicating Poorer Status, Than Scores For 8 Activities Derived From The Health Assessment Questionnaire (HAQ)
Kathryn Gibson¹, Sung-Hoon Park^2,3 and Theodore Pincus⁴, ¹Liverpool Hospital and University of New South Wales, Sydney, Australia, ²NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY, ³Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: The HAQ [Arthritis Rheum 1980;23:137] has been used in almost all rheumatoid arthritis (RA) clinical trials conducted over the last two decades, and provides…
Abstract Number: 1733 • 2013 ACR/ARHP Annual Meeting
Early and Sustained Improvement In Pain and Physical Function As Measured By Visual Analog Scale and Short Form-36 Physical Component Summary Score In Rheumatoid Arthritis Patients Treated With Mavrilimumab, An Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, In a Phase 2a Study
Gerd Burmester¹, Tsutomu Takeuchi², Olga Barbarash³, Duncan Porter⁴, Didier Saurigny⁵, David Close⁵, Alex Godwood⁵, Yoojung Yang⁶ and Ancilla W. Fernandes⁶, ¹Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³SIH Kemerovo Regional Clinical Hospital, Kemerovo, Russia, ⁴Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom, ⁵MedImmune, Ltd, Cambridge, United Kingdom, ⁶MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with significant pain and loss of physical function. We evaluated self-reported pain and physical function in adults patients with…
Abstract Number: 954 • 2012 ACR/ARHP Annual Meeting
Diagnosis of Secondary Fibromyalgia in an Established Rheumatoid Arthritis Cohort
Yvonne C. Lee¹, Christine K. Iannaccone¹, Michelle A. Frits¹, M. Weinblatt² and Nancy A. Shadick³, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The prevalence of fibromyalgia (FM) is 7-10 times higher among rheumatoid arthritis (RA) patients than the general population. However, the diagnosis of FM in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].